Zobrazeno 1 - 10
of 155
pro vyhledávání: '"S Frantal"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
C. Minichsdorfer, T. Fuereder, M. Leutner, C.F. Singer, S. Kacerovsky-Strobl, D. Egle, R. Greil, M. Balic, F. Fitzal, G. Pfeiler, S. Frantal, R. Bartsch, M. Gnant
Publikováno v:
ESMO open. 7(2)
Statins are cholesterol-lowering drugs prescribed for the prevention and treatment of cardiovascular disease. Moreover, statins may possess anticancer properties and interact with receptor activator of nuclear factor κB ligand expression. We aimed a
Autor:
Richard Greil, Elisabeth Bergen, Georg Pfeiler, R. Bartsch, Christoph Minichsdorfer, Florian Fitzal, S Frantal, Günther G. Steger, Viktor Wette, Ruth Exner, Daniel Egle, H Fohler, Marija Balic, M. Gnant
Publikováno v:
Cancer Research. 79:P6-21
This abstract was withdrawn by the authors. Citation Format: Minichsdorfer C, Bergen E, Steger GG, Pfeiler G, Frantal S, Greil R, Fohler H, Egle D, Balic M, Fitzal F, Wette V, Exner R, Bartsch RA, Gnant M. Withdrawn [abstract]. In: Proceedings of the
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. Gnant, Christoph Tinchon, M. Rudas, A Pichler, Marija Balic, Viktor Wette, M-Km Tea, Herbert Stöger, Edgar Petru, Richard Greil, M Hubalek, P Dubsky, Daniel Egle, G Pfeiler, Christian F. Singer, R. Bartsch, P. Sevelda, A. Petzer, S Bago-Horvath, S Frantal
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 14:A1-A53
Autor:
Rupert Bartsch, Richard Greil, P. Sevelda, Georg Pfeiler, G Michael, Daniel Egle, Marija Balic, A Pichler, Zsuzsanna Bago-Horvath, Michael Hubalek, M-Km Tea, Viktor Wette, Edgar Petru, Christian F. Singer, Andreas L. Petzer, Margarethe Rudas, Christoph Tinchon, Herbert Stoeger, P Dubsky, S Frantal
Publikováno v:
Cancer Research. 77:P6-10
Background: Immune-based therapeutic strategies represent a promising approach in early and advanced breast cancer treatment. MUC1 glycoprotein is overexpressed and aberrantly glycosylated in over 90% of malignant breast cancer. It is involved in onc
Autor:
Margaretha Rudas, Richard Greil, Michael Gnant, Gabriel Rinnerthaler, Martin Filipits, L.J. van 't Veer, W. Hulla, Zsuzsanna Bago-Horvath, Peter Dubsky, W Herz, S Frantal, Farid Moinfar, Daniel Egle, Christa Dreezen, E. Lujinovic, J. Buresch
Publikováno v:
ESMO Open
Background MammaPrint is a prognostic assay based on gene expression in tumors from patients with early breast cancer. MammaPrint has been extensively validated and Food and Drug Administration cleared in fresh and formalin-fixed and paraffin-embedde
Autor:
S Frantal, Bernhard Holzner, Michael Gnant, Sonja Heibl, Beate Mayrbaeurl, Josef Thaler, Gudrun Piringer, Monika Sztankay
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Integrative Cancer Therapies
Integrative Cancer Therapies
Purpose: Cancer and its treatment strategies can have adverse effects on physical functioning and quality of life. Treatment strategies for better quality of life are still an unresolved issue. Physical activity is a promising treatment strategy that
Autor:
Daniel Egle, Michael Hubalek, Georg Pfeiler, Marija Balic, Christoph C. Zielinski, S Frantal, Gabriel Rinnerthaler, Barbara Krause, Michael Seifert, Michael Gnant, Michael A. Fridrik, Alois Lang, Christian F. Singer, Guenther G. Steger, Peter Dubsky, Rupert Bartsch, Margaretha Rudas, Theresa Czech, Ruth Exner, Simon Peter Gampenrieder, Andreas L. Petzer, David Mayr, Paul Sevelda, Richard Greil
Publikováno v:
Cancer Research. 75:P3-11
BACKGROUND Pathological complete response (pCR) after neoadjuvant systemic therapy is correlated with better prognosis in HER2-positive, early breast cancer. Bevacizumab (B) was shown to add efficacy to neoadjuvant systemic treatment in HER2-negative
Autor:
Sonja Burgstaller, Michael A. Fridrik, Michael Gnant, Alois Lang, Josef Thaler, S Frantal, Gudrun Piringer, Richard Greil, Wolfgang Eisterer, Andreas Leiherer, J. Tschmelitsch, August Zabernigg, Alfred Fridrik
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 26(4)
Despite advances in adjuvant chemotherapy, 20–30% of patients in stages II–III colorectal cancer will eventually relapse. Observational studies showed a reduction in relapse rate, colon cancer-specific mortality, and overall mortality by physical